ACAD
39.28
+0.06
+0.15%
AEMD
3.776
+0.016
+0.4309%
APRI
3.206
+0.316
+10.9446%
ARNA
1.49
0.00
0.00%
ATEC
2.91
+0.02
+0.69%
CNAT
5.25
+0.03
+0.57%
CRXM
0.255
+0.033
+14.968%
CYTX
1.85
-0.04
-2.12%
DXCM
81.89
+0.5
+0.61%
GNMK
10.545
+0.045
+0.429%
HALO
12.61
+0.05
+0.40%
ILMN
163.37
+2.07
+1.28%
INNV
0.17
+0.01
+6.92%
INO
6.96
-0.04
-0.57%
ISCO
1.04
-0.04
-3.70%
ISIS
57.56
0.00
0.00%
LGND
105.71
+0.38
+0.36%
LPTN
2.93
0.00
0.00%
MBVX
3.01
+0.44
+17.12%
MEIP
1.74
+0.02
+1.16%
MNOV
6.11
+0.03
+0.49%
MRTX
6.2
+0.2
+3.33%
MSTX
0.13
+0.001
+0.6966%
NBIX
44.05
+0.9
+2.09%
NUVA
74.22
+0.25
+0.34%
ONCS
1.4
+0.02
+1.45%
ONVO
2.97
+0.08
+2.77%
OREX
4.38
-0.3
-6.41%
OTIC
15.55
+0.5
+3.32%
QDEL
20.89
+0.2
+0.97%
RCPT
231.96
0.00
0.00%
RGLS
1.15
-0.05
-4.17%
RMD
72.27
+0.35
+0.49%
SCIE
0.001
+0.00
+32.00000%
SPHS
2.76
-0.03
-1.08%
SRNE
5.55
-0.07
-1.33%
TROV
2.1
+0.05
+2.44%
VICL
2.26
-0.01
-0.44%
VOLC
18
0.00
0.00%
ZGNX
10.2
-0.25
-2.39%
ACAD
39.28
+0.06
+0.15%
AEMD
3.776
+0.016
+0.4309%
APRI
3.206
+0.316
+10.9446%
ARNA
1.49
0.00
0.00%
ATEC
2.91
+0.02
+0.69%
CNAT
5.25
+0.03
+0.57%
CRXM
0.255
+0.033
+14.968%
CYTX
1.85
-0.04
-2.12%
DXCM
81.89
+0.5
+0.61%
GNMK
10.545
+0.045
+0.429%
HALO
12.61
+0.05
+0.40%
ILMN
163.37
+2.07
+1.28%
INNV
0.17
+0.01
+6.92%
INO
6.96
-0.04
-0.57%
ISCO
1.04
-0.04
-3.70%
ISIS
57.56
0.00
0.00%
LGND
105.71
+0.38
+0.36%
LPTN
2.93
0.00
0.00%
MBVX
3.01
+0.44
+17.12%
MEIP
1.74
+0.02
+1.16%
MNOV
6.11
+0.03
+0.49%
MRTX
6.2
+0.2
+3.33%
MSTX
0.13
+0.001
+0.6966%
NBIX
44.05
+0.9
+2.09%
NUVA
74.22
+0.25
+0.34%
ONCS
1.4
+0.02
+1.45%
ONVO
2.97
+0.08
+2.77%
OREX
4.38
-0.3
-6.41%
OTIC
15.55
+0.5
+3.32%
QDEL
20.89
+0.2
+0.97%
RCPT
231.96
0.00
0.00%
RGLS
1.15
-0.05
-4.17%
RMD
72.27
+0.35
+0.49%
SCIE
0.001
+0.00
+32.00000%
SPHS
2.76
-0.03
-1.08%
SRNE
5.55
-0.07
-1.33%
TROV
2.1
+0.05
+2.44%
VICL
2.26
-0.01
-0.44%
VOLC
18
0.00
0.00%
ZGNX
10.2
-0.25
-2.39%
Home » Bio: Keith Murphy

Bio: Keith Murphy

Keith Murphy, chairman and chief executive officer, is a veteran of biotechnology startup Alkermes, Inc, where he played a central role on the development team for their first approved product, Nutropin (hGH) Depot. He moved to Amgen in 1997 and developed several other novel formulation and device products. He has more than 17 years of experience in biotechnology, including serving in product strategy and director of process development roles at Amgen. His 10 years at Amgen included four years as global operations leader for the largest development program in Amgen’s history, Phase 3 osteoporosis/bone cancer drug denosumab. He holds a B.S. in chemical engineering from MIT and is an alumnus of the UCLA Anderson School of Management.

Be Sociable, Share!